Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer

Rhea-AI Summary

Ionis Pharmaceuticals (NASDAQ: IONS) announced the appointment of Dr. Eugene Schneider as executive vice president and chief clinical development officer. Since joining Ionis in 2013, he has contributed to over 20 clinical trials globally. Dr. Schneider brings extensive experience from his previous roles, including developing enzyme replacement therapies and overseeing clinical research. His addition is expected to strengthen Ionis' leadership and enhance their portfolio of innovative antisense medicines aimed at treating unmet medical needs. The company boasts a pipeline of over 40 novel therapies.

Positive

• Dr. Eugene Schneider's appointment is expected to enhance leadership in clinical development.
• Over 20 successful clinical trials have been contributed to by Dr. Schneider since 2013.
• Ionis has a robust pipeline with more than 40 novel medicines aimed at unmet medical needs.

Negative

• None.

CARLSBAD, Calif., Jan. 7, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the appointment of Eugene Schneider, M.D., as executive vice president and chief clinical development officer. In this role, Dr. Schneider will oversee clinical development of novel antisense medicines across all of Ionis' therapeutic franchises. He will report to Richard S. Geary, Ph.D., Ionis' executive vice president and chief development officer, and serve on the company's executive team.

Since joining Ionis in 2013, Dr. Schneider has played a key role in more than 20 clinical trials conducted in the U.S. and globally. He is an accomplished biopharmaceutical industry veteran with two decades of experience leading global medical and scientific affairs and the development and commercialization of medicines to treat a range of disorders, including pediatric, rare and central nervous system diseases.

"Dr. Schneider's proven track record overseeing successful studies, assessing risk-benefit profiles of investigational medicines and providing consistent clinical due diligence in safety reporting will strengthen Ionis' industry leadership as we expand our portfolio of wholly owned and partnered medicines and build our commercial organization to maximize the value of our rich pipeline," said Dr. Geary.

"I am excited to join Ionis' talented executive team and look forward to continuing my work with them and all Ionis employees who are deeply committed to delivering potentially transformative medicines to patients who depend on us," said Dr. Schneider.   

Before joining Ionis, Dr. Schneider was senior medical director, clinical research and development at Synageva BioPharma, where he developed a novel enzyme replacement therapy for Lysosomal Acid Lipase Deficiency from its first-in-man study to registration. Prior to Synageva, he was senior medical director, medical and scientific affairs at Biovail Technologies Ltd., where he was primarily responsible for the development and commercialization of a diverse portfolio of medicines designed to address patient needs related to central nervous system disorders.

Dr. Schneider received his medical degree from the University of Medicine and Dentistry of New Jersey and completed his training in pediatric and adolescent medicine at Robert Wood Johnson University Hospital in New Brunswick, New Jersey.

ABOUT IONIS PHARMACEUTICALS, INC. 
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for all patients, children and adults with spinal muscular atrophy, as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to potentially treat a broad range of disease, including neurological, cardio-renal, metabolic, infectious, and pulmonary diseases.

To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/ionis-appoints-eugene-schneider-md-as-executive-vice-president-and-chief-clinical-development-officer-301203128.html

SOURCE Ionis Pharmaceuticals, Inc.

FAQ

Who is Dr. Eugene Schneider and what is his role at Ionis Pharmaceuticals?

Dr. Eugene Schneider is the newly appointed executive vice president and chief clinical development officer at Ionis Pharmaceuticals, overseeing the clinical development of novel antisense medicines.

What experience does Dr. Schneider bring to Ionis Pharmaceuticals?

Dr. Schneider has two decades of experience in the biopharmaceutical industry, having led the development and commercialization of medicines for various disorders, and has participated in over 20 clinical trials.

What is the significance of Dr. Schneider's appointment for Ionis Pharmaceuticals?

His appointment is expected to strengthen Ionis' industry leadership and enhance the clinical development of their expanding portfolio of medicines.

What is Ionis Pharmaceuticals' pipeline like?

Ionis Pharmaceuticals has a pipeline of over 40 novel medicines targeting a wide range of diseases, including neurological, cardio-renal, and metabolic disorders.